PMID- 36559118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221226
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 12
DP  - 2022 Nov 28
TI  - Hybrid Polydimethylsiloxane (PDMS) Incorporated Thermogelling System for 
      Effective Liver Cancer Treatment.
LID - 10.3390/pharmaceutics14122623 [doi]
LID - 2623
AB  - For the delivery of anticancer drugs, an injectable in situ hydrogel with thermal 
      responsiveness and prolonged drug release capabilities shows considerable 
      potential. Here, we present a series of thermosensitive in situ hydrogels that 
      serve as drug delivery systems for the treatment of liver cancer. These hydrogels 
      were created by utilizing the polydimethylsiloxane (PDMS) oligomer, polyethylene 
      glycol (PEG) and polypropylene glycol (PPG)'s chemical cross-linking 
      capabilities. Doxorubicin (DOX) was encapsulated in a hydrogel with a hydrophobic 
      core and hydrophilic shell to enhance DOX solubility. Studies into the behavior 
      of in situ produced hydrogels at the microscopic and macroscopic levels revealed 
      that the copolymer solution exhibits a progressive shift from sol to gel as the 
      temperature rises. The hydrogels' chemical composition, thermal properties, 
      rheological characteristics, gelation period, and DOX release behavior were all 
      reported. Subcutaneous injection in mice was used to confirm the injectability. 
      Through the in vitro release of DOX in a PBS solution that mimics the tumor 
      microenvironment, the hydrogel's sustained drug release behavior was confirmed. 
      Additionally, using human hepatocellular hepatoma, the anticancer efficacy of 
      thermogel (DEP-2@DOX) was assessed (HepG2). The carrier polymer material DEP-2 
      was tested for cytotoxicity using HepG2 cells and its excellent cytocompatibility 
      was confirmed. In conclusion, these thermally responsive injectable hydrogels are 
      prominent potential candidates as drug delivery vehicles for the treatment of 
      hepatocellular carcinoma.
FAU - Ma, Panqin
AU  - Ma P
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Jiang, Lu
AU  - Jiang L
AD  - Department of Biomedical Engineering, School of Biomedical and Pharmaceutical 
      Sciences, Guangdong University of Technology, Guangzhou 510006, China.
FAU - Luo, Xi
AU  - Luo X
AD  - BE/Phase I Clinical Center, The First Affiliated Hospital of Xiamen University, 
      School of Medicine, Xiamen University, Xiamen 361000, China.
FAU - Chen, Jiayun
AU  - Chen J
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Chen, Ying
AU  - Chen Y
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Ye, Enyi
AU  - Ye E
AD  - Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), A*STAR 
      (Agency for Science, Technology and Research), 1 Pesek Road, Jurong Island, 
      Singapore 627833, Singapore.
AD  - Institute of Materials Research and Engineering, A*STAR (Agency for Science, 
      Technology and Research), Singapore 138634, Singapore.
FAU - Loh, Xian Jun
AU  - Loh XJ
AD  - Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), A*STAR 
      (Agency for Science, Technology and Research), 1 Pesek Road, Jurong Island, 
      Singapore 627833, Singapore.
AD  - Institute of Materials Research and Engineering, A*STAR (Agency for Science, 
      Technology and Research), Singapore 138634, Singapore.
FAU - Wu, Caisheng
AU  - Wu C
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Wu, Yun-Long
AU  - Wu YL
AUID- ORCID: 0000-0001-6426-6340
AD  - Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key 
      Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen 
      University, Xiamen 361102, China.
FAU - Li, Zibiao
AU  - Li Z
AUID- ORCID: 0000-0002-0591-5328
AD  - Institute of Sustainability for Chemicals, Energy and Environment (ISCE2), A*STAR 
      (Agency for Science, Technology and Research), 1 Pesek Road, Jurong Island, 
      Singapore 627833, Singapore.
AD  - Institute of Materials Research and Engineering, A*STAR (Agency for Science, 
      Technology and Research), Singapore 138634, Singapore.
LA  - eng
PT  - Journal Article
DEP - 20221128
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC9781567
OTO - NOTNLM
OT  - in situ
OT  - injectable hydrogel
OT  - sustained drug release
OT  - thermal response
COIS- The authors declare no conflict of interest.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/11/28
CRDT- 2022/12/23 01:56
PHST- 2022/11/07 00:00 [received]
PHST- 2022/11/22 00:00 [revised]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2022/12/23 01:56 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/11/28 00:00 [pmc-release]
AID - pharmaceutics14122623 [pii]
AID - pharmaceutics-14-02623 [pii]
AID - 10.3390/pharmaceutics14122623 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Nov 28;14(12):2623. doi: 10.3390/pharmaceutics14122623.